Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 141
Filtrar
Más filtros

Banco de datos
País/Región como asunto
Tipo del documento
Intervalo de año de publicación
1.
Cell ; 157(1): 255-66, 2014 Mar 27.
Artículo en Inglés | MEDLINE | ID: mdl-24679540

RESUMEN

Isolation of genes encoding the receptors for steroids, retinoids, vitamin D, and thyroid hormone and their structural and functional analysis revealed an evolutionarily conserved template for nuclear hormone receptors. This discovery sparked identification of numerous genes encoding related proteins, termed orphan receptors. Characterization of these orphan receptors and, in particular, of the retinoid X receptor (RXR) positioned nuclear receptors at the epicenter of the "Big Bang" of molecular endocrinology. This Review provides a personal perspective on nuclear receptors and explores their integrated and coordinated signaling networks that are essential for multicellular life, highlighting the RXR heterodimer and its associated ligands and transcriptional mechanism.


Asunto(s)
Receptores Citoplasmáticos y Nucleares/metabolismo , Receptores X Retinoide/metabolismo , Transducción de Señal , Animales , Endocrinología , Regulación de la Expresión Génica , Humanos , Receptores Citoplasmáticos y Nucleares/química , Receptores X Retinoide/química , Transcripción Genética
2.
Cell ; 159(6): 1478.e1, 2014 Dec 04.
Artículo en Inglés | MEDLINE | ID: mdl-25480303

RESUMEN

Specialized endocrine cells secrete a variety of peptide hormones all along the gastrointestinal (GI) tract, making it one of the largest endocrine organs in the body. Nutrients and developmental and neural cues trigger the secretion of gastrointestinal (GI) hormones from specialized endocrine cells along the GI tract. These hormones act in target tissues to facilitate digestion and regulate energy homeostasis. This SnapShot summarizes the production and functions of GI hormones.


Asunto(s)
Tracto Gastrointestinal/metabolismo , Tracto Gastrointestinal/fisiología , Hormonas/fisiología , Animales , Tracto Gastrointestinal/química , Humanos
3.
Cell ; 148(3): 556-67, 2012 Feb 03.
Artículo en Inglés | MEDLINE | ID: mdl-22304921

RESUMEN

Fibroblast growth factor-21 (FGF21) is a circulating hepatokine that beneficially affects carbohydrate and lipid metabolism. Here, we report that FGF21 is also an inducible, fed-state autocrine factor in adipose tissue that functions in a feed-forward loop to regulate the activity of peroxisome proliferator-activated receptor γ (PPARγ), a master transcriptional regulator of adipogenesis. FGF21 knockout (KO) mice display defects in PPARγ signaling including decreased body fat and attenuation of PPARγ-dependent gene expression. Moreover, FGF21-KO mice are refractory to both the beneficial insulin-sensitizing effects and the detrimental weight gain and edema side effects of the PPARγ agonist rosiglitazone. This loss of function in FGF21-KO mice is coincident with a marked increase in the sumoylation of PPARγ, which reduces its transcriptional activity. Adding back FGF21 prevents sumoylation and restores PPARγ activity. Collectively, these results reveal FGF21 as a key mediator of the physiologic and pharmacologic actions of PPARγ.


Asunto(s)
Factores de Crecimiento de Fibroblastos/metabolismo , Hipoglucemiantes/uso terapéutico , PPAR gamma/metabolismo , Tiazolidinedionas/uso terapéutico , Adipocitos/metabolismo , Tejido Adiposo Blanco/metabolismo , Animales , Comunicación Autocrina , Resistencia a Medicamentos , Factores de Crecimiento de Fibroblastos/genética , Hipoglucemiantes/efectos adversos , Metabolismo de los Lípidos , Lipodistrofia/genética , Lipodistrofia/metabolismo , Hígado/efectos de los fármacos , Hígado/metabolismo , Ratones , Ratones Noqueados , PPAR gamma/agonistas , Comunicación Paracrina , Rosiglitazona , Sumoilación , Tiazolidinedionas/efectos adversos , Transcripción Genética
4.
Genes Dev ; 33(15-16): 1083-1094, 2019 08 01.
Artículo en Inglés | MEDLINE | ID: mdl-31296559

RESUMEN

The orphan nuclear receptor SHP (small heterodimer partner) is a well-known transcriptional corepressor of bile acid and lipid metabolism in the liver; however, its function in other tissues is poorly understood. Here, we report an unexpected role for SHP in the exocrine pancreas as a modulator of the endoplasmic reticulum (ER) stress response. SHP expression is induced in acinar cells in response to ER stress and regulates the protein stability of the spliced form of X-box-binding protein 1 (XBP1s), a key mediator of ER stress response. Loss of SHP reduces XBP1s protein level and transcriptional activity, which in turn attenuates the ER stress response during the fasting-feeding cycle. Consequently, SHP-deficient mice also are more susceptible to cerulein-induced pancreatitis. Mechanistically, we show that SHP physically interacts with the transactivation domain of XBP1s, thereby inhibiting the polyubiquitination and degradation of XBP1s by the Cullin3-SPOP (speckle-type POZ protein) E3 ligase complex. Together, our data implicate SHP in governing ER homeostasis and identify a novel posttranslational regulatory mechanism for the key ER stress response effector XBP1.


Asunto(s)
Estrés del Retículo Endoplásmico/genética , Proteolisis , Receptores Citoplasmáticos y Nucleares/metabolismo , Proteína 1 de Unión a la X-Box/metabolismo , Células Acinares/metabolismo , Animales , Perfilación de la Expresión Génica , Regulación de la Expresión Génica/genética , Células HEK293 , Humanos , Ratones , Ratones Endogámicos C57BL , Páncreas Exocrino/metabolismo , Pancreatitis/genética , Empalme de Proteína , Estabilidad Proteica , Receptores Citoplasmáticos y Nucleares/deficiencia , Receptores Citoplasmáticos y Nucleares/genética , Ubiquitinación/genética
5.
Proc Natl Acad Sci U S A ; 118(8)2021 02 23.
Artículo en Inglés | MEDLINE | ID: mdl-33602820

RESUMEN

DAF-12 is nematode-specific nuclear receptor that has been proposed to govern development of the infectious stage of parasitic species, including Strongyloides stercoralis Here, we identified a parasite-specific coactivator, called DAF-12 interacting protein-1 (DIP-1), that is required for DAF-12 ligand-dependent transcriptional activity. DIP-1 is found only in Strongyloides spp. and selectively interacts with DAF-12 through an atypical receptor binding motif. Using CRISPR/Cas9-directed mutagenesis, we demonstrate that DAF-12 is required for the requisite developmental arrest and the ligand-dependent reactivation of infectious S. stercoralis infective third-stage larvae, and that these effects require the DIP-1 coactivator. These studies reveal the existence of a distinct nuclear receptor/coactivator signaling pathway that governs parasite development.


Asunto(s)
Proteínas de Caenorhabditis elegans/metabolismo , Caenorhabditis elegans/crecimiento & desarrollo , Regulación del Desarrollo de la Expresión Génica , Larva/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Strongyloides stercoralis/parasitología , Factores de Transcripción/metabolismo , Secuencia de Aminoácidos , Animales , Secuencia de Bases , Sistemas CRISPR-Cas , Caenorhabditis elegans/genética , Caenorhabditis elegans/metabolismo , Proteínas de Caenorhabditis elegans/genética , Larva/genética , Larva/crecimiento & desarrollo , Receptores Citoplasmáticos y Nucleares/genética , Strongyloides stercoralis/genética , Factores de Transcripción/genética
6.
PLoS Pathog ; 17(12): e1010140, 2021 12.
Artículo en Inglés | MEDLINE | ID: mdl-34910770

RESUMEN

Schistosomes infect over 200 million of the world's poorest people, but unfortunately treatment relies on a single drug. Nuclear hormone receptors are ligand-activated transcription factors that regulate diverse processes in metazoans, yet few have been functionally characterized in schistosomes. During a systematic analysis of nuclear receptor function, we found that an FTZ-F1-like receptor was essential for parasite survival. Using a combination of transcriptional profiling and chromatin immunoprecipitation (ChIP), we discovered that the micro-exon gene meg-8.3 is a transcriptional target of SmFTZ-F1. We found that both Smftz-f1 and meg-8.3 are required for esophageal gland maintenance as well as integrity of the worm's head. Together, these studies define a new role for micro-exon gene function in the parasite and suggest that factors associated with the esophageal gland could represent viable therapeutic targets.


Asunto(s)
Esófago/metabolismo , Regulación de la Expresión Génica/fisiología , Proteínas del Helminto/metabolismo , Schistosoma mansoni/metabolismo , Factores de Transcripción/metabolismo , Animales
7.
Proc Natl Acad Sci U S A ; 115(48): 12102-12111, 2018 11 27.
Artículo en Inglés | MEDLINE | ID: mdl-30420515

RESUMEN

The nuclear receptor peroxisome proliferator-activated receptor γ (PPARγ) is a master regulator of adipocyte differentiation and is the target for the insulin-sensitizing thiazolidinedione (TZD) drugs used to treat type 2 diabetes. In cell-based in vitro studies, the transcriptional activity of PPARγ is inhibited by covalent attachment of small ubiquitin-related modifier (SUMOylation) at K107 in its N terminus. However, whether this posttranslational modification is relevant in vivo remains unclear. Here, using mice homozygous for a mutation (K107R) that prevents SUMOylation at this position, we demonstrate that PPARγ is SUMOylated at K107 in white adipose tissue. We further show that in the context of diet-induced obesity PPARγ-K107R-mutant mice have enhanced insulin sensitivity without the corresponding increase in adiposity that typically accompanies PPARγ activation by TZDs. Accordingly, the PPARγ-K107R mutation was weaker than TZD treatment in stimulating adipocyte differentiation in vitro. Moreover, we found that both the basal and TZD-dependent transcriptomes of inguinal and epididymal white adipose tissue depots were markedly altered in the K107R-mutant mice. We conclude that PPARγ SUMOylation at K107 is physiologically relevant and may serve as a pharmacologic target for uncoupling PPARγ's beneficial insulin-sensitizing effect from its adverse effect of weight gain.


Asunto(s)
Adiposidad , Insulina/metabolismo , Lisina/metabolismo , Obesidad/metabolismo , PPAR gamma/metabolismo , Tejido Adiposo/metabolismo , Secuencias de Aminoácidos , Animales , Femenino , Humanos , Lisina/genética , Masculino , Ratones , Mutación Missense , Obesidad/genética , Obesidad/fisiopatología , PPAR gamma/química , PPAR gamma/genética , Proteína SUMO-1 , Sumoilación
8.
Proc Natl Acad Sci U S A ; 115(1): 204-209, 2018 01 02.
Artículo en Inglés | MEDLINE | ID: mdl-29203662

RESUMEN

Strongyloides stercoralis hyperinfection causes high mortality rates in humans, and, while hyperinfection can be induced by immunosuppressive glucocorticoids, the pathogenesis remains unknown. Since immunocompetent mice are resistant to infection with S. stercoralis, we hypothesized that NSG mice, which have a reduced innate immune response and lack adaptive immunity, would be susceptible to the infection and develop hyperinfection. Interestingly, despite the presence of large numbers of adult and first-stage larvae in S. stercoralis-infected NSG mice, no hyperinfection was observed even when the mice were treated with a monoclonal antibody to eliminate residual granulocyte activity. NSG mice were then infected with third-stage larvae and treated for 6 wk with methylprednisolone acetate (MPA), a synthetic glucocorticoid. MPA treatment of infected mice resulted in 50% mortality and caused a significant >10-fold increase in the number of parasitic female worms compared with infected untreated mice. In addition, autoinfective third-stage larvae, which initiate hyperinfection, were found in high numbers in MPA-treated, but not untreated, mice. Remarkably, treatment with Δ7-dafachronic acid, an agonist of the parasite nuclear receptor Ss-DAF-12, significantly reduced the worm burden in MPA-treated mice undergoing hyperinfection with S. stercoralis Overall, this study provides a useful mouse model for S. stercoralis autoinfection and suggests a therapeutic strategy for treating lethal hyperinfection.


Asunto(s)
Colestenos/farmacología , Metilprednisolona/análogos & derivados , Strongyloides stercoralis/inmunología , Estrongiloidiasis/tratamiento farmacológico , Estrongiloidiasis/inmunología , Animales , Colestenos/efectos adversos , Femenino , Metilprednisolona/efectos adversos , Metilprednisolona/farmacología , Acetato de Metilprednisolona , Ratones , Estrongiloidiasis/patología
9.
Genes Dev ; 26(4): 312-24, 2012 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-22302876

RESUMEN

We review the physiology and pharmacology of two atypical fibroblast growth factors (FGFs)-FGF15/19 and FGF21-that can function as hormones. Both FGF15/19 and FGF21 act on multiple tissues to coordinate carbohydrate and lipid metabolism in response to nutritional status. Whereas FGF15/19 is secreted from the small intestine in response to feeding and has insulin-like actions, FGF21 is secreted from the liver in response to extended fasting and has glucagon-like effects. FGF21 also acts in an autocrine fashion in several tissues, including adipose. The pharmacological actions of FGF15/19 and FGF21 make them attractive drug candidates for treating metabolic disease.


Asunto(s)
Factores de Crecimiento de Fibroblastos/metabolismo , Animales , Ácidos y Sales Biliares/metabolismo , Ayuno/fisiología , Factores de Crecimiento de Fibroblastos/farmacología , Homeostasis/efectos de los fármacos , Homeostasis/fisiología , Humanos , Neoplasias/metabolismo
10.
Proc Natl Acad Sci U S A ; 113(4): 1026-31, 2016 Jan 26.
Artículo en Inglés | MEDLINE | ID: mdl-26755598

RESUMEN

Age-related thymic degeneration is associated with loss of naïve T cells, restriction of peripheral T-cell diversity, and reduced healthspan due to lower immune competence. The mechanistic basis of age-related thymic demise is unclear, but prior evidence suggests that caloric restriction (CR) can slow thymic aging by maintaining thymic epithelial cell integrity and reducing the generation of intrathymic lipid. Here we show that the prolongevity ketogenic hormone fibroblast growth factor 21 (FGF21), a member of the endocrine FGF subfamily, is expressed in thymic stromal cells along with FGF receptors and its obligate coreceptor, ßKlotho. We found that FGF21 expression in thymus declines with age and is induced by CR. Genetic gain of FGF21 function in mice protects against age-related thymic involution with an increase in earliest thymocyte progenitors and cortical thymic epithelial cells. Importantly, FGF21 overexpression reduced intrathymic lipid, increased perithymic brown adipose tissue, and elevated thymic T-cell export and naïve T-cell frequencies in old mice. Conversely, loss of FGF21 function in middle-aged mice accelerated thymic aging, increased lethality, and delayed T-cell reconstitution postirradiation and hematopoietic stem cell transplantation (HSCT). Collectively, FGF21 integrates metabolic and immune systems to prevent thymic injury and may aid in the reestablishment of a diverse T-cell repertoire in cancer patients following HSCT.


Asunto(s)
Envejecimiento/inmunología , Factores de Crecimiento de Fibroblastos/fisiología , Inmunosenescencia , Timo/inmunología , Animales , Ratones , Ratones Endogámicos C57BL , Receptores de Antígenos de Linfocitos T/fisiología , Linfocitos T/inmunología
11.
Genes Dev ; 25(16): 1674-9, 2011 Aug 15.
Artículo en Inglés | MEDLINE | ID: mdl-21852532

RESUMEN

We have determined the cistrome and transcriptome for the nuclear receptor liver receptor homolog-1 (LRH-1) in exocrine pancreas. Chromatin immunoprecipitation (ChIP)-seq and RNA-seq analyses reveal that LRH-1 directly induces expression of genes encoding digestive enzymes and secretory and mitochondrial proteins. LRH-1 cooperates with the pancreas transcription factor 1-L complex (PTF1-L) in regulating exocrine pancreas-specific gene expression. Elimination of LRH-1 in adult mice reduced the concentration of several lipases and proteases in pancreatic fluid and impaired pancreatic fluid secretion in response to cholecystokinin. Thus, LRH-1 is a key regulator of the exocrine pancreas-specific transcriptional network required for the production and secretion of pancreatic fluid.


Asunto(s)
Redes Reguladoras de Genes , Páncreas Exocrino/metabolismo , Receptores Citoplasmáticos y Nucleares/genética , Factores de Transcripción/genética , Animales , Antineoplásicos Hormonales/farmacología , Secuencia de Bases , Western Blotting , Inmunoprecipitación de Cromatina , Regulación hacia Abajo/efectos de los fármacos , Femenino , Perfilación de la Expresión Génica , Humanos , Lipasa/genética , Lipasa/metabolismo , Masculino , Ratones , Ratones Noqueados , Ratones Transgénicos , Datos de Secuencia Molecular , Páncreas Exocrino/efectos de los fármacos , Péptido Hidrolasas/genética , Péptido Hidrolasas/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Reacción en Cadena de la Polimerasa de Transcriptasa Inversa , Homología de Secuencia de Aminoácido , Tamoxifeno/farmacología , Factores de Transcripción/metabolismo
12.
PLoS Pathog ; 12(1): e1005358, 2016 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-26727267

RESUMEN

The complex life cycle of the parasitic nematode Strongyloides stercoralis leads to either developmental arrest of infectious third-stage larvae (iL3) or growth to reproductive adults. In the free-living nematode Caenorhabditis elegans, analogous determination between dauer arrest and reproductive growth is governed by dafachronic acids (DAs), a class of steroid hormones that are ligands for the nuclear hormone receptor DAF-12. Biosynthesis of DAs requires the cytochrome P450 (CYP) DAF-9. We tested the hypothesis that DAs also regulate S. stercoralis development via DAF-12 signaling at three points. First, we found that 1 µM Δ7-DA stimulated 100% of post-parasitic first-stage larvae (L1s) to develop to free-living adults instead of iL3 at 37°C, while 69.4±12.0% (SD) of post-parasitic L1s developed to iL3 in controls. Second, we found that 1 µM Δ7-DA prevented post-free-living iL3 arrest and stimulated 85.2±16.9% of larvae to develop to free-living rhabditiform third- and fourth-stages, compared to 0% in the control. This induction required 24-48 hours of Δ7-DA exposure. Third, we found that the CYP inhibitor ketoconazole prevented iL3 feeding in host-like conditions, with only 5.6±2.9% of iL3 feeding in 40 µM ketoconazole, compared to 98.8±0.4% in the positive control. This inhibition was partially rescued by Δ7-DA, with 71.2±16.4% of iL3 feeding in 400 nM Δ7-DA and 35 µM ketoconazole, providing the first evidence of endogenous DA production in S. stercoralis. We then characterized the 26 CYP-encoding genes in S. stercoralis and identified a homolog with sequence and developmental regulation similar to DAF-9. Overall, these data demonstrate that DAF-12 signaling regulates S. stercoralis development, showing that in the post-parasitic generation, loss of DAF-12 signaling favors iL3 arrest, while increased DAF-12 signaling favors reproductive development; that in the post-free-living generation, absence of DAF-12 signaling is crucial for iL3 arrest; and that endogenous DA production regulates iL3 activation.


Asunto(s)
Colestenos/metabolismo , Proteínas del Helminto/metabolismo , Strongyloides stercoralis/crecimiento & desarrollo , Strongyloides stercoralis/metabolismo , Secuencia de Aminoácidos , Animales , Modelos Animales de Enfermedad , Perros , Regulación del Desarrollo de la Expresión Génica/fisiología , Genes de Helminto , Gerbillinae , Proteínas del Helminto/genética , Larva/metabolismo , Estadios del Ciclo de Vida , Receptores Citoplasmáticos y Nucleares/genética , Receptores Citoplasmáticos y Nucleares/metabolismo , Strongyloides stercoralis/genética , Estrongiloidiasis/metabolismo
13.
PLoS Genet ; 11(3): e1005027, 2015 Mar.
Artículo en Inglés | MEDLINE | ID: mdl-25774872

RESUMEN

Appropriate nutrient response is essential for growth and reproduction. Under favorable nutrient conditions, the C. elegans nuclear receptor DAF-12 is activated by dafachronic acids, hormones that commit larvae to reproductive growth. Here, we report that in addition to its well-studied role in controlling developmental gene expression, the DAF-12 endocrine system governs expression of a gene network that stimulates the aerobic catabolism of fatty acids. Thus, activation of the DAF-12 transcriptome coordinately mobilizes energy stores to permit reproductive growth. DAF-12 regulation of this metabolic gene network is conserved in the human parasite, Strongyloides stercoralis, and inhibition of specific steps in this network blocks reproductive growth in both of the nematodes. Our study provides a molecular understanding for metabolic adaptation of nematodes to their environment, and suggests a new therapeutic strategy for treating parasitic diseases.


Asunto(s)
Proteínas de Caenorhabditis elegans/metabolismo , Caenorhabditis elegans/crecimiento & desarrollo , Caenorhabditis elegans/metabolismo , Proteínas del Helminto/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Strongyloides stercoralis/crecimiento & desarrollo , Strongyloides stercoralis/metabolismo , Animales , Ácidos Grasos/metabolismo
14.
Proc Natl Acad Sci U S A ; 111(2): 839-44, 2014 Jan 14.
Artículo en Inglés | MEDLINE | ID: mdl-24379397

RESUMEN

Small heterodimer partner (SHP) is an orphan nuclear receptor that functions as a transcriptional repressor to regulate bile acid and cholesterol homeostasis. Although the precise mechanism whereby SHP represses transcription is not known, E1A-like inhibitor of differentiation (EID1) was isolated as a SHP-interacting protein and implicated in SHP repression. Here we present the crystal structure of SHP in complex with EID1, which reveals an unexpected EID1-binding site on SHP. Unlike the classical cofactor-binding site near the C-terminal helix H12, the EID1-binding site is located at the N terminus of the receptor, where EID1 mimics helix H1 of the nuclear receptor ligand-binding domain. The residues composing the SHP-EID1 interface are highly conserved. Their mutation diminishes SHP-EID1 interactions and affects SHP repressor activity. Together, these results provide important structural insights into SHP cofactor recruitment and repressor function and reveal a conserved protein interface that is likely to have broad implications for transcriptional repression by orphan nuclear receptors.


Asunto(s)
Modelos Moleculares , Proteínas Nucleares/química , Conformación Proteica , Receptores Citoplasmáticos y Nucleares/química , Proteínas Represoras/química , Ácidos y Sales Biliares/metabolismo , Sitios de Unión/genética , Proteínas de Ciclo Celular , Línea Celular , Colesterol/metabolismo , Cristalización , Diseño de Fármacos , Homeostasis/genética , Homeostasis/fisiología , Humanos , Receptores Citoplasmáticos y Nucleares/metabolismo
15.
Dig Dis ; 33(3): 327-31, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26045265

RESUMEN

While it has long been recognized that bile acids are essential for solubilizing lipophilic nutrients in the small intestine, the discovery in 1999 that bile acids serve as ligands for the nuclear receptor farnesoid X receptor (FXR) opened the floodgates in terms of characterizing their actions as selective signaling molecules. Bile acids act on FXR in ileal enterocytes to induce the expression of fibroblast growth factor (FGF)15/19, an atypical FGF that functions as a hormone. FGF15/19 subsequently acts on a cell surface receptor complex in hepatocytes to repress bile acid synthesis and gluconeogenesis, and to stimulate glycogen and protein synthesis. FGF15/19 also stimulates gallbladder filling. Thus, the bile acid-FXR-FGF15/19 signaling pathway regulates diverse aspects of the postprandial enterohepatic response. Pharmacologically, this endocrine pathway provides exciting new opportunities for treating metabolic disease and bile acid-related disorders such as primary biliary cirrhosis and bile acid diarrhea. Both FXR agonists and FGF19 analogs are currently in clinical trials.


Asunto(s)
Ácidos y Sales Biliares/metabolismo , Factores de Crecimiento de Fibroblastos/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Transducción de Señal , Animales , Colesterol 7-alfa-Hidroxilasa/genética , Enterocitos/metabolismo , Factores de Crecimiento de Fibroblastos/genética , Regulación de la Expresión Génica , Gluconeogénesis , Glucógeno/biosíntesis , Homeostasis , Humanos , Resistencia a la Insulina , Metabolismo de los Lípidos , Ratones , Receptores Citoplasmáticos y Nucleares/genética
16.
Proc Natl Acad Sci U S A ; 109(8): 3143-8, 2012 Feb 21.
Artículo en Inglés | MEDLINE | ID: mdl-22315431

RESUMEN

The endocrine hormone fibroblast growth factor 21 (FGF21) is a powerful modulator of glucose and lipid metabolism and a promising drug for type 2 diabetes. Here we identify FGF21 as a potent regulator of skeletal homeostasis. Both genetic and pharmacologic FGF21 gain of function lead to a striking decrease in bone mass. In contrast, FGF21 loss of function leads to a reciprocal high-bone-mass phenotype. Mechanistically, FGF21 inhibits osteoblastogenesis and stimulates adipogenesis from bone marrow mesenchymal stem cells by potentiating the activity of peroxisome proliferator-activated receptor γ (PPAR-γ). Consequently, FGF21 deletion prevents the deleterious bone loss side effect of the PPAR-γ agonist rosiglitazone. Therefore, FGF21 is a critical rheostat for bone turnover and a key integrator of bone and energy metabolism. These results reveal that skeletal fragility may be an undesirable consequence of chronic FGF21 administration.


Asunto(s)
Resorción Ósea/patología , Factores de Crecimiento de Fibroblastos/metabolismo , PPAR gamma/metabolismo , Adipogénesis/efectos de los fármacos , Animales , Médula Ósea/efectos de los fármacos , Médula Ósea/patología , Resorción Ósea/metabolismo , Huesos/efectos de los fármacos , Huesos/metabolismo , Huesos/patología , Resistencia a Medicamentos/efectos de los fármacos , Factores de Crecimiento de Fibroblastos/administración & dosificación , Factores de Crecimiento de Fibroblastos/farmacología , Humanos , Ratones , Ratones Noqueados , Tamaño de los Órganos/efectos de los fármacos , Osteoblastos/efectos de los fármacos , Osteoblastos/metabolismo , Osteoblastos/patología , Osteogénesis/efectos de los fármacos , Osteoprotegerina/metabolismo , Ligando RANK/metabolismo , Rosiglitazona , Tiazolidinedionas/farmacología
17.
Nat Med ; 13(10): 1185-92, 2007 Oct.
Artículo en Inglés | MEDLINE | ID: mdl-17873880

RESUMEN

The cardioprotective effects of estrogen are mediated by receptors expressed in vascular cells. Here we show that 27-hydroxycholesterol (27HC), an abundant cholesterol metabolite that is elevated with hypercholesterolemia and found in atherosclerotic lesions, is a competitive antagonist of estrogen receptor action in the vasculature. 27HC inhibited both the transcription-mediated and the non-transcription-mediated estrogen-dependent production of nitric oxide by vascular cells, resulting in reduced estrogen-induced vasorelaxation of rat aorta. Furthermore, increasing 27HC levels in mice by diet-induced hypercholesterolemia, pharmacologic administration or genetic manipulation (by knocking out the gene encoding the catabolic enzyme CYP7B1) decreased estrogen-dependent expression of vascular nitric oxide synthase and repressed carotid artery reendothelialization. As well as antiestrogenic effects, there were proestrogenic actions of 27HC that were cell-type specific, indicating that 27HC functions as an endogenous selective estrogen receptor modulator (SERM). Taken together, these studies point to 27HC as a contributing factor in the loss of estrogen protection from vascular disease.


Asunto(s)
Cardiotónicos/antagonistas & inhibidores , Cardiotónicos/farmacología , Estrógenos/farmacología , Hidroxicolesteroles/farmacología , Moduladores Selectivos de los Receptores de Estrógeno/farmacología , Animales , Aorta Torácica/efectos de los fármacos , Unión Competitiva/efectos de los fármacos , Cardiotónicos/metabolismo , Técnicas de Cultivo de Célula , Línea Celular , Células Cultivadas , Colesterol en la Dieta/administración & dosificación , ADN Complementario , Relación Dosis-Respuesta a Droga , Esquema de Medicación , Estrógenos/metabolismo , Femenino , Glutatión Transferasa/metabolismo , Humanos , Hidroxicolesteroles/administración & dosificación , Hidroxicolesteroles/sangre , Concentración 50 Inhibidora , Inyecciones Subcutáneas , Riñón/citología , Cinética , Masculino , Ratones , Ratones Noqueados , Óxido Nítrico/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo II/antagonistas & inhibidores , Óxido Nítrico Sintasa de Tipo III , ARN Mensajero/metabolismo , Receptores de Estrógenos/antagonistas & inhibidores , Receptores de Estrógenos/genética , Proteínas Recombinantes de Fusión/antagonistas & inhibidores , Moduladores Selectivos de los Receptores de Estrógeno/administración & dosificación , Moduladores Selectivos de los Receptores de Estrógeno/sangre , Vasodilatación/efectos de los fármacos
18.
J Biol Chem ; 287(49): 41334-41, 2012 Nov 30.
Artículo en Inglés | MEDLINE | ID: mdl-23038264

RESUMEN

Fibroblast growth factor 19 (FGF19) is a postprandial enterokine induced by the nuclear bile acid receptor, FXR, in ileum. FGF19 inhibits bile acid synthesis in liver through transcriptional repression of cholesterol 7α-hydroxylase (CYP7A1) via a mechanism involving the nuclear receptor SHP. Here, in a series of loss-of-function studies, we show that the nuclear receptors HNF4α and LRH-1 have dual roles in regulating Cyp7a1 in vivo. First, they cooperate in maintaining basal Cyp7a1 expression. Second, they enable SHP binding to the Cyp7a1 promoter and facilitate FGF19-mediated repression of bile acid synthesis. HNF4α and LRH-1 promote active transcription histone marks on the Cyp7a1 promoter that are reversed by FGF19 in a SHP-dependent manner. These findings demonstrate that both HNF4α and LRH-1 are important regulators of Cyp7a1 transcription in vivo.


Asunto(s)
Colesterol 7-alfa-Hidroxilasa/biosíntesis , Regulación de la Expresión Génica , Factor Nuclear 4 del Hepatocito/fisiología , Receptores Citoplasmáticos y Nucleares/fisiología , Animales , Ácidos y Sales Biliares/metabolismo , Sitios de Unión , Factores de Crecimiento de Fibroblastos/metabolismo , Células HEK293 , Histonas/metabolismo , Humanos , Hígado/metabolismo , Ratones , Regiones Promotoras Genéticas , Proteína Tirosina Fosfatasa no Receptora Tipo 6/metabolismo , Receptores Citoplasmáticos y Nucleares/metabolismo , Transcripción Genética
19.
J Biol Chem ; 287(7): 4894-903, 2012 Feb 10.
Artículo en Inglés | MEDLINE | ID: mdl-22170062

RESUMEN

Bile acid-like molecules named dafachronic acids (DAs) control the dauer formation program in Caenorhabditis elegans through the nuclear receptor DAF-12. This mechanism is conserved in parasitic nematodes to regulate their dauer-like infective larval stage, and as such, the DAF-12 ligand binding domain has been identified as an important therapeutic target in human parasitic hookworm species that infect more than 600 million people worldwide. Here, we report two x-ray crystal structures of the hookworm Ancylostoma ceylanicum DAF-12 ligand binding domain in complex with DA and cholestenoic acid (a bile acid-like metabolite), respectively. Structure analysis and functional studies reveal key residues responsible for species-specific ligand responses of DAF-12. Furthermore, DA binds to DAF-12 mechanistically and is structurally similar to bile acids binding to the mammalian bile acid receptor farnesoid X receptor. Activation of DAF-12 by cholestenoic acid and the cholestenoic acid complex structure suggest that bile acid-like signaling pathways have been conserved in nematodes and mammals. Together, these results reveal the molecular mechanism for the interplay between parasite and host, provide a structural framework for DAF-12 as a promising target in treating nematode parasitism, and provide insight into the evolution of gut parasite hormone-signaling pathways.


Asunto(s)
Ancylostoma/química , Ácidos y Sales Biliares/química , Colestenos/química , Proteínas del Helminto/química , Receptores Citoplasmáticos y Nucleares/química , Ancylostoma/genética , Ancylostoma/metabolismo , Anquilostomiasis/metabolismo , Anquilostomiasis/terapia , Animales , Ácidos y Sales Biliares/genética , Ácidos y Sales Biliares/metabolismo , Colestenos/metabolismo , Cristalografía por Rayos X , Proteínas del Helminto/genética , Proteínas del Helminto/metabolismo , Mamíferos , Receptores Citoplasmáticos y Nucleares/genética , Receptores Citoplasmáticos y Nucleares/metabolismo , Homología Estructural de Proteína
20.
Am J Physiol Gastrointest Liver Physiol ; 304(4): G371-80, 2013 Feb 15.
Artículo en Inglés | MEDLINE | ID: mdl-23257920

RESUMEN

Bile acid sequestrants are nonabsorbable resins designed to treat hypercholesterolemia by preventing ileal uptake of bile acids, thus increasing catabolism of cholesterol into bile acids. However, sequestrants also improve hyperglycemia and hyperinsulinemia through less characterized metabolic and molecular mechanisms. Here, we demonstrate that the bile acid sequestrant, colesevelam, significantly reduced hepatic glucose production by suppressing hepatic glycogenolysis in diet-induced obese mice and that this was partially mediated by activation of the G protein-coupled bile acid receptor TGR5 and glucagon-like peptide-1 (GLP-1) release. A GLP-1 receptor antagonist blocked suppression of hepatic glycogenolysis and blunted but did not eliminate the effect of colesevelam on glycemia. The ability of colesevelam to induce GLP-1, lower glycemia, and spare hepatic glycogen content was compromised in mice lacking TGR5. In vitro assays revealed that bile acid activation of TGR5 initiates a prolonged cAMP signaling cascade and that this signaling was maintained even when the bile acid was complexed to colesevelam. Intestinal TGR5 was most abundantly expressed in the colon, and rectal administration of a colesevelam/bile acid complex was sufficient to induce portal GLP-1 concentration but did not activate the nuclear bile acid receptor farnesoid X receptor (FXR). The beneficial effects of colesevelam on cholesterol metabolism were mediated by FXR and were independent of TGR5/GLP-1. We conclude that colesevelam administration functions through a dual mechanism, which includes TGR5/GLP-1-dependent suppression of hepatic glycogenolysis and FXR-dependent cholesterol reduction.


Asunto(s)
Alilamina/análogos & derivados , Péptido 1 Similar al Glucagón/metabolismo , Receptores Acoplados a Proteínas G/fisiología , Alilamina/farmacología , Animales , Ácidos y Sales Biliares/farmacología , Glucemia/efectos de los fármacos , Glucemia/metabolismo , Colesterol/metabolismo , Clorhidrato de Colesevelam , Dieta Alta en Grasa , Receptor del Péptido 1 Similar al Glucagón , Glucogenólisis/efectos de los fármacos , Hígado/efectos de los fármacos , Masculino , Ratones , Ratones Obesos , Receptores Citoplasmáticos y Nucleares/antagonistas & inhibidores , Receptores de Glucagón/metabolismo
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA